|
|||||
|
|
Neither in vivo MRI nor behavioural assessment indicate therapeutic efficacy for a novel 5HT1A agonist in rat models of ischaemic stroke |
|
| Authors: | Maria Ashioti John S Beech Andrew S Lowe Michel Bernanos Andrew McCreary Michel M Modo Steve CR Williams |
| Affiliation: | (1) Neuroimaging Research Group, Clinical Neuroscience, Institute of Psychiatry, Kings College London, De Crespigny Park, PO42, SE5 8AF Denmark Hill, London, UK;(2) Department of Medicine, University of Cambridge,Addenbrooke's Hospital, Hills Road, Cambridge, UK;(3) Solvay Pharmaceuticals, C.J. van Houtenlaan 36, 1381, CP, Weesp, the Netherlands |
| Abstract: | Background5HT1A agonists have previously been shown to promote recovery in animal models of stroke using ex vivo outcome measures which have raised the hopes for a potential clinical implementation. The purpose of this study was to evaluate the potential neuroprotective properties of a novel 5HT1A agonist DU123015 in 2 different models of transient focal ischaemic stroke of varying severities using both in vivo neuroimaging and behavioural techniques as primary outcome measures. For these studies, the NMDA receptor antagonist MK-801 was also utilized as a positive control to further assess the effectiveness of the stroke models and techniques used. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |